$0.2100
-1.93-90.19%
Last update: Oct 2, 4:05 PM
$0.2100
-1.93-90.19%
EAGLE PHARMS INC by Eagle Pharmaceuticals, Inc.
EGRXOTCEM
EAGLE PHARMS INC by Eagle Pharmaceuticals, Inc. (EGRX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
EAGLE PHARMS INC by Eagle Pharmaceuticals, Inc. (EGRX) last issued guidance on September 7, 2023 for fiscal year 2023. The company guided earnings per share in the range of $4.4 - $4.7, compared to a consensus EPS estimate of $4.58.
Compared to prior guidance, EAGLE PHARMS INC by Eagle Pharmaceuticals, Inc. maintained its EPS outlook from a previous range of $4.4 - $4.7.
EAGLE PHARMS INC by Eagle Pharmaceuticals, Inc. has issued 9 guidance updates between January 10, 2023 and September 7, 2023. During this period, the company raised its outlook 2 times, reflecting management's growing confidence in business performance.
| Metric | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $1.05 | $1.05 | $0.83 | $0.91 |
| Actual | $1.18 | $1.26 | $1.10 | $1.12 |
| Surprise | +12.4% | +20.0% | +32.5% | +23.1% |
| Revenue | ||||
| Estimate | $59.4M | $63.3M | $64.3M | $62.1M |
| Actual | $64.6M | $66.3M | $60.7M | $65.9M |
| Surprise | +8.92% | +4.76% | -5.54% | +6.15% |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 8, 2023 | $1.18 | $1.05 | 12.4 % |
| Q1 | May 9, 2023 | $1.26 | $1.05 | 20.0 % |
| Q4 | Mar 13, 2023 | $1.10 | $0.83 | 32.5 % |
| Q3 | Nov 7, 2022 | $1.12 | $0.91 | 23.1 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 8, 2023 | $64.65M | $59.35M | 8.92 % |
| Q1 | May 9, 2023 | $66.31M | $63.29M | 4.76 % |
| Q4 | Mar 13, 2023 | $60.70M | $64.26M | -5.54 % |
| Q3 | Nov 7, 2022 | $65.90M | $62.08M | 6.15 % |
